Results of an antimicrobial stewardship program
- Conditions
- Infectious diseasesCommunicable DiseasesInfectionEnvironmental Illness
- Registration Number
- RPCEC00000275
- Lead Sponsor
- Pharmaceutical Promotion and Prevention Research Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 514
1. Patient older than 18 years.
2. Patients who, within their pharmacotherapy, have a minimum prescribed one of the following antibiotics:
• Penicillins: Piperacillin / Tazobactam.
• Cephalosporins: Ceftriaxone, Ceftazidime, Cefepime, Ceftaroline.
• Carbapenems: Meropenem, Doripenem, Imipenem / Cilastatin, Ertapenem.
• Quinolones: Ciprofloxacin.
• Glycopeptides: Vancomycin.
• Polymyxins: Polymyxin B, Colistin
• Oxazolidinones: Linezolid.
• Cyclic lipopeptides: Daptomycin.
• Tetracyclines: Tigecycline.
1. Patients without the first evaluation by the treating medical specialty.
2. Patients receiving extracorporeal membrane oxygenation (ECMO).
3. Patients with cystic fibrosis. and. Administration of antimicrobials subcutaneously, intraperitoneally or intrathecally.
4. Patients admitted to surgery and hemodynamics.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.